Delay In Canadian Approval For Semaglutide Was Unexpected Onesource Specialty Pharma Cnbc Tv18

Sun Pharma Labs Gets Cdsco Panel Nod To Study Synthetic Origin Audio tracks for some languages were automatically generated. learn more. Shares of onesource specialty pharma ltd. plunged as much as 18% after the company reported a sharply weaker december quarter. the sell off was triggered by a delay in semaglutide approval in canada, which materially impacted revenues and profitability.

When Was Semaglutide Approved A Look Back Glp 1 Health Dr. reddy’s laboratories, the indian pharmaceutical company, was among the first to file a generic semaglutide submission with health canada. on october 30, 2025, the company received a notice of non compliance (non) — effectively a rejection of its initial application. Dr. reddy's laboratories received a notice of non compliance from canada's pharmaceutical drugs directorate regarding its semaglutide generic drug submission, delaying the anticipated launch. Dr reddy's labs may face an 8 12 month delay in launching its semaglutide generic in canada after receiving a non compliance notice from health canada. January 4, 2026 was a significant date for canadians who pay out of pocket for semaglutide. that day, novo nordisk’s data exclusivity on the drug expired — making canada the first major western market where generic manufacturers could legally file for approval. nine companies filed submissions.

When Was Semaglutide Approved A Look Back Glp 1 Health Dr reddy's labs may face an 8 12 month delay in launching its semaglutide generic in canada after receiving a non compliance notice from health canada. January 4, 2026 was a significant date for canadians who pay out of pocket for semaglutide. that day, novo nordisk’s data exclusivity on the drug expired — making canada the first major western market where generic manufacturers could legally file for approval. nine companies filed submissions. Canada was among the first countries where semaglutide — a medication used to manage type 2 diabetes and promote weight loss — lost patent protection. but lower cost generic versions are still. Onesource specialty pharma: betting on semaglutide scale up and canada opportunity onesource specialty pharma is primarily a fill and finish manufacturer for semaglutide injections, meaning it undertakes the final stage of production before the drug is shipped to pharmaceutical companies. Dr. reddy's laboratories is still awaiting approval for semaglutide in canara, sources with knowledge of the matter told cnbc tv18. shares of dr. reddy's laboratories gained as much as 8% on thursday in anticipation of this approval, marking the biggest single day gain for the stock since may 2022. Dr. reddy's laboratories ltd. confirmed a cnbc tv18 newsbreak on friday, april 24, when it confirmed to the exchanges that it is still awaiting approval for its semaglutide injection from the canadian health regulator.